2010
DOI: 10.1007/s00423-010-0680-8
|View full text |Cite
|
Sign up to set email alerts
|

Impact of thyroid nodular disease on 99mTc-sestamibi scintigraphy in patients with primary hyperparathyroidism

Abstract: In patients with coexisting thyroid disease but not thyroidectomy needed, MIBI scintigraphy contributes to the detection of a solitary adenoma. When thyroid resection is required, MIBI imaging is often negative.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

2
13
0

Year Published

2010
2010
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 24 publications
(15 citation statements)
references
References 14 publications
(11 reference statements)
2
13
0
Order By: Relevance
“…This is considerably lower than reported in first-time surgery, reflecting that this patient subgroup is more likely to have multigland disease, smaller volume disease or concurrent thyroid disease, which are all known to lower the efficacy of localisation studies. [11][12][13][14] Over a quarter (28%) of the patients in our series had concurrent thyroid disease. 4D CT is currently the second-line investigation for patients with negative conventional parathyroid imaging.…”
Section: Discussionmentioning
confidence: 81%
“…This is considerably lower than reported in first-time surgery, reflecting that this patient subgroup is more likely to have multigland disease, smaller volume disease or concurrent thyroid disease, which are all known to lower the efficacy of localisation studies. [11][12][13][14] Over a quarter (28%) of the patients in our series had concurrent thyroid disease. 4D CT is currently the second-line investigation for patients with negative conventional parathyroid imaging.…”
Section: Discussionmentioning
confidence: 81%
“…Thirteen studies were prospective [10][11][12][16][17][18][19][20][21][22][23][24][25] and 15 were retrospective. 4,5,[26][27][28][29][30][31][32][33][34][35][36][37][38] Levels of evidence analysis were determined to be level III (cohort studies) and V (case series). The main concerns regarding study quality were: minor variations in patient inclusion criteria, potential bias in patient selection inherent to retrospective studies, and heterogeneity in the reporting of data and summary statistics.…”
Section: Quality Of Included Studiesmentioning
confidence: 99%
“…4,5,[10][11][12]17,19,20,22,23,30,31 Dual-phase 99m Tc-sestamibi (MIBI) was assessed in 13 studies. 4,10,11,[19][20][21]24,[28][29][30]32,37,38 Based on 11 studies, 4,10,11,19,20,22,24,28,31,32,38 MIBI had a pooled sensitivity of 0.76 (95% CI 0.71-0.80) and PPV of 0.86 (95% CI 0.82-0.90). Interestingly, some of these studies (n 5 10) also included comparative cohorts without concurrent thyroid pathology showing sensitivity of MIBI ranging from 0.63 to 1.00 and PPV from 0.92 to 1.00.…”
Section: Imaging Modalitiesmentioning
confidence: 99%
“…21,22 The Tc-MIBI scan is not specific for parathyroid tissue, and thyroid nodules also accumulate Tc-MIBI. 23 In selected cases with a single adenoma and a positive scan and, if possible, without thyroid nodular disease, this new device may replace the intraoperative measurement of iPTH. However, in unselected cases, in conjunction with radio-guided surgery, the intraoperative iPTH assay is considered to be an important tool in surgery for PHPT.…”
mentioning
confidence: 99%